Published in Am Heart J on July 01, 1999
Impact of specialist follow-up in outpatients with congestive heart failure. CMAJ (2005) 2.50
Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial. Heart (2007) 1.91
Association of diastolic dysfunction and outcomes in ambulatory older adults with chronic heart failure. J Gerontol A Biol Sci Med Sci (2005) 1.64
Clinical implications of an accurate problem list on heart failure treatment. J Gen Intern Med (2005) 1.38
Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev (2002) 0.96
Trends in quality of care among patients with incident heart failure in Denmark 2003-2010: a nationwide cohort study. BMC Health Serv Res (2013) 0.86
Exploratory cost-effectiveness analysis of cardiac resynchronization therapy with systematic device optimization vs. standard (non-systematic) optimization: a multinational economic evaluation. Health Econ Rev (2015) 0.81
Contemporary issues in heart failure. Am Heart J (1999) 0.78
A cluster randomized trial to assess the impact of opinion leader endorsed evidence summaries on improving quality of prescribing for patients with chronic cardiovascular disease: rationale and design [ISRCTN26365328]. BMC Cardiovasc Disord (2005) 0.76
Referral and use of heart failure clinics: what factors are related to use? Can J Cardiol (2012) 0.75
Type 2 Diabetes and Heart Failure: Challenges and Solutions. Curr Cardiol Rev (2016) 0.75
Cardiac resynchronization: a brief synopsis part I: patient selection and results from clinical trials. J Interv Card Electrophysiol (2003) 0.75
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) Lancet (2000) 8.01
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med (1996) 5.94
Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ (2001) 5.63
Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med (2000) 5.41
A systematic review of randomized trials of disease management programs in heart failure. Am J Med (2001) 5.38
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 4.36
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med (1995) 4.29
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med (1995) 3.69
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 3.61
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med (1996) 2.79
Acetaminophen treatment nomogram. N Engl J Med (1994) 2.69
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation (1994) 2.61
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation (2000) 2.49
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem (1998) 2.27
A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications. J Am Coll Cardiol (1999) 2.24
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 2.23
Contemporary practice patterns in the management of newly diagnosed hypertension. CMAJ (1997) 2.23
Acute precipitants of congestive heart failure exacerbations. Arch Intern Med (2001) 2.11
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation (1998) 2.09
One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation (1996) 2.03
Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo. Circulation (1992) 1.97
Reproducibility and validity of a food frequency questionnaire among fourth to seventh grade inner-city school children: implications of age and day-to-day variation in dietary intake. Public Health Nutr (1999) 1.94
Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol (1996) 1.91
Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation (1996) 1.86
Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol (1991) 1.78
Body surface potential mapping of ST segment changes in acute myocardial infarction. Implications for ECG enrollment criteria for thrombolytic therapy. Circulation (1993) 1.74
Ethnic differences in the relationships between obesity and glucose-metabolic abnormalities: a cross-sectional population-based study. Int J Obes (Lond) (2005) 1.72
In vivo right heart thrombus. Precursor of life-threatening pulmonary embolism. Chest (1988) 1.72
Endocarditis due to Q fever in Nova Scotia: experience with five patients in 1981-1982. J Infect Dis (1983) 1.64
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J (2004) 1.59
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J (2001) 1.58
Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia (1995) 1.58
A mammalian mitochondrial serine transfer RNA lacking the "dihydrouridine" loop and stem. Nucleic Acids Res (1980) 1.56
Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. Circulation (2001) 1.56
Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation (1990) 1.55
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J (2000) 1.55
Exposure to the mass media and weight concerns among girls. Pediatrics (1999) 1.54
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart (2008) 1.54
Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis (1996) 1.53
Activity, inactivity, and obesity: racial, ethnic, and age differences among schoolgirls. Am J Public Health (1993) 1.53
Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial. Eur Heart J (1996) 1.52
Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. Stat Med (1990) 1.50
Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. J Natl Cancer Inst (1991) 1.49
Comparison of risk and patterns of practice in patients older and younger than 70 years with acute myocardial infarction in a two-year period (1987-1989) Am J Cardiol (1991) 1.48
Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators) J Am Coll Cardiol (1996) 1.48
Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators. Can J Cardiol (2000) 1.47
Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group. J Am Coll Cardiol (1991) 1.45
Malignant granular cell tumors: report of a case and review of the literature. Surgery (1994) 1.43
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. Eur Heart J (2003) 1.42
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost (2005) 1.42
Angiographic morphology in unstable angina pectoris. Am J Cardiol (1988) 1.42
Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol (1992) 1.41
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission? Eur Heart J (2003) 1.40
Heparin in acute coronary disease--requiem for a heavyweight? N Engl J Med (1997) 1.39
Acute reduction of lipoprotein(a) by tissue-type plasminogen activator. Circulation (1992) 1.39
Management of asymptomatic chronic aortic regurgitation with left ventricular dysfunction: a decision analysis. J Gen Intern Med (1990) 1.39
Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol (2000) 1.39
Prognosis in medically stabilized unstable angina: early Holter ST-segment monitoring compared with predischarge exercise thallium tomography. Ann Intern Med (1990) 1.38
Comparative response of male and female patients with coronary artery disease to exercise rehabilitation. Eur Heart J (1984) 1.38
Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation (1986) 1.38
Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med (1991) 1.36
Comparison of the appropriateness of coronary angiography and coronary artery bypass graft surgery between Canada and New York State. JAMA (1994) 1.35
Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE). Indian Heart J (2001) 1.33
Behaviour of canine pulmonary vagal afferent receptors during sustained acute pulmonary venous pressure elevation. J Physiol (1987) 1.32
The influence of changes in blood volume on angina pectoris. A study of the effect of phlebotomy. Circulation (1970) 1.29
Chronic false aneurysms of the left ventricle: management revisited. Can J Cardiol (1994) 1.28
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. J Am Coll Cardiol (2001) 1.27
Swallow syncope. Can Med Assoc J (1985) 1.24
Failure to detect vertical transmission of hepatitis C virus. Ann Intern Med (1992) 1.23
Blood levels after sublingual nitroglycerin. Circulation (1979) 1.22
The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. Can J Cardiol (1998) 1.22
Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation (1999) 1.21
Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother (1994) 1.20
Acute occlusion of the infrarenal aorta. Am J Surg (1973) 1.20
Abnormal cardiac enzyme responses after strenuous exercise: alternative diagnostic aids. Br Med J (Clin Res Ed) (1982) 1.19
Platelet-endothelial cell adhesion molecule-1 (CD31), a scaffolding molecule for selected catenin family members whose binding is mediated by different tyrosine and serine/threonine phosphorylation. J Biol Chem (2000) 1.18
Putative measure of peripheral and brainstem frequency-following in humans. Neurosci Lett (2000) 1.18
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol (1996) 1.17
The management of congestive heart failure. Postgrad Med J (1997) 1.16
Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. Arch Intern Med (1987) 1.16
Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res (1994) 1.16
Mortality risk and patterns of practice in 2,070 patients with acute myocardial infarction, 1987-92. Relative importance of age, sex, and medical therapy. Chest (1994) 1.15